Journals / Klinik Psikofarmakoloji Bülteni / 2013 / Cilt: 23 - Sayı: 3

Şizofreni ve şizoaffektif bozuklukta medial prefrontal korteks nörokimyasal metabolit- ler: Bir proton MRS çalışması

Medial prefrontal cortex neurochemical metabolites in schizophrenia and schizoaffective disorder: A proton magnetic resonance spectroscopy study

Pages
215–223
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, the decreases in Cr and myo-I levels in schizoaffective disorder patients point to abnormalities in energy metabolism and glial cells in the medial prefrontal region.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to investigate medial prefrontal cortex neurochemical metabolite levels in patients with schizophrenia and schizoaffective disorder.
📊
Key Findings & Data:Method: The subjects comprised 15 patients with schizophrenia (SCH), 15 patients with schizoaffective disorder (SAD), and 15 healthy controls.
💡
Conclusion & Impact:In addition, the decreases in Cr and myo-I levels in schizoaffective disorder patients point to abnormalities in energy metabolism and glial cells in the medial prefrontal region.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to investigate medial prefrontal cortex neurochemical metabolite levels in patients with schizophrenia and schizoaffective disorder. Method: The subjects comprised 15 patients with schizophrenia (SCH), 15 patients with schizoaffective disorder (SAD), and 15 healthy controls. Levels of N-acetyl aspartate (NAA), choline-containing compounds (Cho), creatine-containing compounds (Cr), and myo-inositol (myo-I) were measured in the medial prefrontal cortex (mPFC) using 1H-MRS. Results: Differences were detected in NAA, Cho, Cr, and myo-I levels among the groups. In schizophrenic patients, the left and right mPFC NAA levels and left mPFC Cho level were found to be lower, compared to the control group. In patients with schizoaffective disorder, left and right mPFC NAA, Cho, Cr, and myo-I levels were found to be lower compared to the control group. No difference was detected in mPFC neurochemical metabolite levels between schizophrenia and schizoaffective disorder patients. Conclusion: In this stud were found that in schizophrenia and schizoaffective disorder, NAA and Cho levels are reduced. Consequently, in these two diseases, neuronal activity and neuronal integrity are impaired in the medial prefrontal region, and there are defects in membrane phospholipid metabolism. In addition, the decreases in Cr and myo-I levels in schizoaffective disorder patients point to abnormalities in energy metabolism and glial cells in the medial prefrontal region.

Özet

Amaç: Bu çalışmada, şizofreni ve şizoaffektif bozuklukta medial prefrontal korteks nörokimyasal metabolit düzeylerinin araştırılması amaçlanmıştır. Yöntem: Çalışmaya 15 şizofreni (SCH), 15 şizoaffektif bozukluğu (SAD) olan hasta ve 15 sağlıklı kontrol katıldı. Medial prefrontal korteks (mPFC) N-asetil aspartat (NAA), kreatin içeren bileşikler (Cr), kolin içeren bileşikler (Cho) ve myo-inozitol (myo-I) düzeyleri proton manyetik rezonans spektroskopi (1H-MRS) ile araştırıldı. Bulgular: Gruplar arasında NAA, Cr, Cho ve myo-I düzeylerinde farklılık olduğu tespit edildi. Şizofreni hastalarında sağ ve sol mPFC NAA düzeyleri, sol mPFC Cho düzeyi kontrol grubuna göre düşük bulundu. Şizoaffektif bozukluğu olan hastalarda sağ ve sol mPFC NAA, Cho, Cr ve myo-I düzeyleri kontrol grubuna göre düşük bulundu. Şizofreni ve şizoaffektif bozukluk arasında mPFC nörokimyasal metabolit düzeylerinde fark- lılık saptanmadı. Sonuç: Bu çalışmada şizofreni ve şizoaffektif bozuklukta NAA ve Cho düzeylerinin azaldığını, dolayısıyla bu iki hastalıkta medial prefrontal bölgede nöronal canlılık ve bütünlüğün bozulduğunu, membran fosfolipid metabolizmasında düzensizlikler olduğu bulundu. Şizoaffektif bozuklukta Cr ve myo-I düzeylerinde de azalma olması bu bozuklukta medial prefrontal bölgede enerji metabolizmasında ve glial hücrelerde anormallikler olduğuna işaret etmektedir.

🔖

Cite This Article

OZDEL, O., SOZERİ, G. V., KALAYCI, D., TOKER, T. U., TUMKAYA, S., KİROGLU, Y. (2022). Şizofreni ve şizoaffektif bozuklukta medial prefrontal korteks nörokimyasal metabolit- ler: Bir proton MRS çalışması. Klinik Psikofarmakoloji Bülteni, Cilt: 23 - Sayı: 3, 215–223. https://ajindex.com/articles/574078

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. American Psychiatric Assocation. Diagnostic and Statical Manual of Mental Disorders (DSM-IV). Washington DC: APA Press, 1994
  2. Kendler KS, McGuire M, Gruenberg AM, Walsh D. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study. Am J Psychiatry 1995;152(5):755-64
  3. Harrow M, Grossman LS, Herbener ES, Davies EW. Ten- year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry 2000;177:421-6
  4. Monkul ES, Yildiz A, Soares JC. Magnetic Resonance Spectroscopy (MRS) applications in bipolar disorder. Turkish Journal of Psychiatry 2004;15(2):138-47. (Turkish
  5. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(6):969-95
  6. Omori M, Murata T, Kimura H, Koshimoto Y, Kada H, Ishimori Y, Ito H, Wada Y. Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res 2000;98(3):155-62
  7. Block W, Bayer TA, Tepest R, Träber F, Rietschel M, Müller DJ, Schulze TG, Honer WG, Maier W, Schild HH, Falkai P. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett 2000;289(2):147-51
  8. Yamasue H, Fukui T, Fukuda R, Yamada H, Yamasaki S, Kuroki N, Abe O, Kasai K, Tsujii K, Iwanami A, Aoki S, Ohtomo K, Kato N, Kato T. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 2002;13(16):2133-7
  9. Théberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003;160(12):2231-3
  10. Wood SJ, Yücel M, Wellard RM, Harrison BJ, Clarke K, Fornito A, Velakoulis D, Pantelis C. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res 2007;94(1-3):328-31
  11. Yoo SY, Yeon S, Choi CH, Kang DH, Lee JM, Shin NY, Jung WH, Choi JS, Jang DP, Kwon JS. Proton magnetic resonance spectroscopy